Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH. Rahim MK, et al. Among authors: fong l. Cell. 2023 Mar 16;186(6):1127-1143.e18. doi: 10.1016/j.cell.2023.02.021. Cell. 2023. PMID: 36931243 Free PMC article.
Immunotherapy for prostate cancer.
Fong L, Small EJ. Fong L, et al. Semin Oncol. 2003 Oct;30(5):649-58. doi: 10.1016/s0093-7754(03)00350-6. Semin Oncol. 2003. PMID: 14571412 Review.
Immunotherapy for prostate cancer.
Fong L, Small EJ. Fong L, et al. Curr Urol Rep. 2006 May;7(3):239-46. doi: 10.1007/s11934-006-0027-8. Curr Urol Rep. 2006. PMID: 16630528 Review.
Immunotherapy for prostate cancer.
Fong L, Small EJ. Fong L, et al. Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z. Curr Oncol Rep. 2007. PMID: 17430695 Review.
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG. Spitzer MH, et al. Among authors: fong l. Cell. 2017 Jan 26;168(3):487-502.e15. doi: 10.1016/j.cell.2016.12.022. Epub 2017 Jan 19. Cell. 2017. PMID: 28111070 Free PMC article.
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. Wang D, et al. Among authors: fong l. Cell Rep. 2018 Jun 12;23(11):3262-3274. doi: 10.1016/j.celrep.2018.05.050. Cell Rep. 2018. PMID: 29898397 Free PMC article.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. Pai CS, et al. Among authors: fong l. J Clin Invest. 2019 Jan 2;129(1):349-363. doi: 10.1172/JCI123391. Epub 2018 Dec 10. J Clin Invest. 2019. PMID: 30530991 Free PMC article.
681 results